AiSuDa (ivarmacitinib)

PARITY: Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors (clinicaltrials.gov)

Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study (clinicaltrials.gov)

Evaluation of Efficacy and Safety of Ivarmacitinib Tablets in Adults with Moderate to Severe Hidradenitis Suppurativa: A Prospective, Single-Arm, Multicenter Study (ChiCTR2600121030)

Efficacy and Safety of Withdrawing Ivarmacitinib or Conventional Synthetic DMARDs in Rheumatoid Arthritis Patients Achieving Low Disease Activity After Combination Therapy: A Prospective, Multicenter, Randomized Controlled Study (ChiCTR2600119971)

A prospective, single-arm, multicenter study of Camrelizumab combined with chemotherapy and Ivarmacitinib as first-line treatment for advanced NSCLC (ChiCTR2600119574)

The Efficacy and Safety of Imatinib in Treating Refractory Alopecia Areata: A Prospective, Single-Arm, Exploratory Study (ChiCTR2600119138)

Efficacy and safety of Ivarmacitinib in patients with active ankylosing spondylitis:A prospective, multicenter real world study (ChiCTR2600118422)

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (clinicaltrials.gov)

Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis (clinicaltrials.gov)

A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation (clinicaltrials.gov)

A randomized, double-blinded, placebo-controlled clinical trial of the efficacy and safety of SHR-0302 combine with Prednisone Acetate in the treatment of active arteritis (ChiCTR2500114756)